Ankylosing Spondylitis Treatment Guidelines

Introduction to Ankylosing Spondylitis Treatment

• The American College of Rheumatology recommends TNF inhibitors as the first-line biologic treatment for patients with active ankylosing spondylitis despite NSAID therapy, with no single TNF inhibitor preferred over another for axial disease unless specific contraindications exist 1, 2

First-Line Biologic Selection

• The American College of Rheumatology strongly recommends initiating TNF inhibitors in patients with persistently high disease activity despite conventional NSAID treatment 3, 1
• Available TNF inhibitors, including infliximab, adalimumab, etanercept, certolizumab, and golimumab, demonstrate comparable efficacy for axial manifestations 3, 1
• No particular TNF inhibitor is recommended as the preferred choice for standard axial disease 1

Special Considerations

Inflammatory Bowel Disease

• The American College of Rheumatology prefers TNF monoclonal antibodies, such as infliximab, adalimumab, certolizumab, and golimumab, over etanercept in patients with concomitant inflammatory bowel disease 3, 5

Uveitis

• Extra-articular manifestations, including uveitis, should be managed in collaboration with ophthalmology specialists 3

Treatment Failure and Switching Strategies

Primary Non-Response

• The American College of Rheumatology conditionally recommends switching to IL-17 inhibitors, such as secukinumab or ixekizumab, over trying a different TNF inhibitor in cases of primary non-response 1, 4
• Primary non-response is defined as the absence of clinically meaningful improvement over 3-6 months after treatment initiation 4

Secondary Non-Response

• The American College of Rheumatology recommends switching to a different TNF inhibitor over switching to IL-17 inhibitors in cases of secondary non-response 1, 2
• Secondary loss of response justifies either switching to another TNF inhibitor or dose escalation of the current agent 2
• Switching to a second TNF blocker may be beneficial, especially in patients with loss of response 3

Critical Treatment Principles

Monotherapy vs. Combination

• The American College of Rheumatology recommends continuing TNF inhibitor monotherapy rather than adding conventional DMARDs, such as methotrexate or sulfasalazine, for axial disease 1, 5
• There is no evidence supporting the obligatory use of DMARDs before or concomitant with anti-TNF therapy for axial manifestations 3
• Sulfasalazine may be considered only for peripheral arthritis, not axial disease 3, 5

Duration and Discontinuation

• Biologics should not be discontinued as a standard approach, as discontinuation leads to disease flares in 60-74% of patients 2, 5
• Dose tapering is conditionally recommended against as a standard approach 1, 5
• Long-term continuous treatment is generally recommended to maintain disease control 5

Monitoring Requirements

• Regular monitoring of disease activity using validated measures, such as BASDAI or ASDAS, is recommended 5
• Monitor CRP or ESR every 3-4 months during biologic therapy 5, 4
• Assess cardiovascular risk and screen for osteoporosis, as these comorbidities are increased in ankylosing spondylitis 3